Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial-Reference-Cited by-同舟云学术

Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial

Published:2004-01-15 Issue:2 Volume:189 Page:265-272
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:J INFECT DIS

Author:

Eron Joseph J.,Feinberg Judith,Kessler Harold A.,Horowitz Harold W.,Witt Mallory D.,Carpio Felix F.,Wheeler David A.,Ruane Peter,Mildvan Donna,Yangco Bienvenido G.,Bertz Richard,Bernstein Barry,King Martin S.,Sun Eugene

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/189/2/265/2652460/189-2-265.pdf

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPEUTIC STRATEGIES AND USE OF LOPINAVIR/RITONAVIR IN PATIENTS WITH HIGHLY RESISTANT HUMAN IMMUNODEFICIENCY VIRUS;FARMACIA;2024

2. Simulation of optimal dose regimens of photoactivated curcumin for antimicrobial resistance pneumonia in COVID-19 patients: A modeling approach;Infectious Disease Modelling;2023-09

3. In Silico Prediction of Andrographolide Dosage Regimens for COVID-19 Treatment;The American Journal of Chinese Medicine;2022-01

4. The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection.;Acta Biomedica Scientifica;2021-12-28

5. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation;Drug Metabolism and Disposition;2021-08-23